2016Unpublished venueOpen access

Bone Radionuclide Imaging, Quantitation and Bone Densitometry

Glen Mervyn Blake, Ignac Fogelman

Open full text 6 citations

Abstract

Radionuclide bone imaging is a common investigation performed in most nuclear medicine departments. In early days, 87mSr was the bone agent used and interest in 99mTc for Nuclear Medicine imaging began in the early 1960’s. The first technetium labelled bone agent, 99mTc-polyphosphate, was described by Subramanian and McAfee in 1971. Recent years have seen a further change in the choice of optimum tracer as the wider availability of PET scanners has brought renewed interest in 18F-fluoride. The 99mTc-MDP bone scan is an old and trusted friend that continues to perform with some distinction, but it is apparent that we can do significantly better with 18F. This chapters summarises, the growth and expansion of Bone Radionuclide Imaging, Quantitation and Bone Densitometry in the UK. These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Open-access reader

About this research paper

What this paper is about

Radionuclide bone imaging is a common investigation performed in most nuclear medicine departments. In early days, 87mSr was the bone agent used and interest in 99mTc for Nuclear Medicine imaging began in the early 1960’s. The first technetium labelled bone agent, 99mTc-polyphosphate, was described by Subramanian and McAfee in 1971. Recent years have seen a further change in the choice of optimum tracer as the wider availability of PET scanners has brought renewed interest in 18F-fluoride. The 99mTc-MDP bone scan is an old and trusted friend that continues to perform with some distinction, but it is apparent that we can do significantly better with 18F. This chapters summarises, the growth and expansion of Bone Radionuclide Imaging, Quantitation and Bone Densitometry in the UK. These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Why it matters

OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Radionuclide bone imaging is a common investigation performed in most nuclear medicine departments. In early days, 87mSr was the bone agent used and interest in 99mTc for Nuclear Medicine imaging began in the early 1960’s. The first technetium labelled bone agent, 99mTc-polyphosphate, was described by Subramanian and McAfee in 1971. Recent years have seen a further change in the choice of optimum tracer as the wider availability of PET scanners has brought renewed interest in 18F-fluoride. The 99mTc-MDP bone scan is an old and trusted friend that continues to perform with some distinction, but it is apparent that we can do significantly better with 18F. This chapters summarises, the growth and expansion of Bone Radionuclide Imaging, Quantitation and Bone Densitometry in the UK. These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Key concepts: Bone imaging, Radionuclide, Densitometry, Radionuclide imaging, Nuclear medicine, Technetium-99, Medicine, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Bone Radionuclide Imaging, Quantitation and Bone Densitometry — Research Paper | ScholarLens